Product Description :

Issue :

SFDA has issued a recall of one batche of Zicarb-200  tablet due to the product incompliance with the requirements of the executive regulations for the Pharmaceutical establishments system.

Recommendations :

For healthcare professionals: Stop dispensing the affected batche immediately. Embargo/Quarantine all remaining stock. Affected batches should be returned to the supplier.

For patients,

1. Consult your healthcare provider prior to discontinuing use of the affected batche, or for any health concerns.
2. Contact the recalling firm or SFDA if you have any questions about the recall.
3. Adverse reactions or quality problems experienced with the use of this product may be reported to Saudi Vigilance either online or call center (Call 19999).